Form 8-K












Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 15, 2014




(Exact Name of Registrant as Specified in Charter)




Delaware   001-36296   26-2025616

(State or Other Jurisdiction

of Incorporation)



File Number)


(IRS Employer

Identification No.)


215 First Street, Suite 400

Cambridge, MA

(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 871-9911


(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 2.02 Results of Operations and Financial Condition

On May 15, 2014, Eleven Biotherapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2014. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information provided under this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.


Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:


99.1    Press release issued by the Company on May 15, 2014


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: May 15, 2014     By:  

/s/ Abbie C. Celniker


Abbie C. Celniker, Ph.D.

President & Chief Executive Officer





Description of Exhibit

99.1    Press release issued by the Company on May 15, 2014

Exhibit 99.1



Eleven Biotherapeutics Reports Fiscal First Quarter 2014 Financial Results

- Enrollment Complete in EBI-005 Phase 2 Allergic Conjunctivitis Study -

Management to host conference call today at 8:30 am ET

CAMBRIDGE, Mass.—(BUSINESS WIRE)—May 15, 2014—Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results and operational highlights for the quarter ended March 31, 2014.

“Eleven Biotherapeutics is off to a strong start in 2014,” stated Abbie Celniker, President and Chief Executive Officer. “We are pleased to announce that we completed patient enrollment in the EBI-005 Phase 2 clinical trial for allergic conjunctivitis and are on-track to report top-line clinical data in the fourth quarter of 2014 as planned. In addition, our pivotal Phase 3 clinical study of EBI-005 in dry eye disease continues to enroll patients on schedule, and our plan to initiate a twelve-month safety study with EBI-005 is also on track for the second half of this year.”

“Earlier this year, we completed our initial public offering, improving our balance sheet and attracting a number of new shareholders, and strengthened our leadership team with the appointments of ophthalmology industry veterans to our board and management team. We were also pleased by the interest of the medical and scientific community in the data we presented at a number of ophthalmology industry conferences this spring, including clinical data on EBI-005, the first IL-1 (Interleukin-1) signaling inhibitor designed for topical ocular administration, and preclinical data on EBI-029, an IL-6 (Interleukin-6) inhibitor optimized for localized ocular administration in diabetic macular edema.”

First Quarter 2014 and Recent Business Highlights:



    Initiated a pivotal Phase 3 clinical study with EBI-005 in dry eye disease with top-line results expected in early 2015.


    Initiated and completed patient enrollment in a Phase 2 clinical trial of EBI-005 for the treatment of allergic conjunctivitis with top-line results expected in the fourth quarter of 2014.


    Presented at a number of ophthalmology industry conferences including:


    Association for Research in Vision and Ophthalmology (ARVO) 2014 Annual Meeting, at which Eleven Biotherapeutics researchers gave three poster presentations elaborating on Eleven’s understanding of cytokine biology to target the treatment of front and back of eye diseases. These posters included clinical data on EBI-005 demonstrating improvements in signs and symptoms in patients with dry eye disease through IL-1 Inhibition, and preclinical data on EBI-029 demonstrating inhibition of IL-6 as a validated target for treating diabetic macular edema.



2014 American Society of Cataract and Refractive Surgery (ASCRS) Annual Symposium, at which Michael H. Goldstein, M.D., M.B.A., Eleven Biotherapeutics’ Vice President of Clinical Research and co-director of the Cornea, External Disease and Cataract Service group at Tufts University/ New England Eye Center, presented




Phase 1b/2a clinical data on Eleven’s lead product candidate EBI-005 for the treatment of dry eye disease. Dr. Goldstein received the honor of a ‘Best Paper in Session’ award and was listed in Eye World Today and the ASCRS meeting newspaper.


    2014 Ophthalmology Innovation Summit (OIS) @ American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, at which Abbie Celniker participated in a session, along with other industry leaders, on the topic of dry eye disease. The participants in the session, who represented a cross section of industry and scientific thought leaders, discussed the role dry eye technologies and therapies play in ophthalmic practice.


    World Ophthalmology Congress (WOC) 2014, at which Michael Goldstein, M.D., presented on the topic of IL-1 inhibition for dry eye disease and highlighted EBI-005 clinical data as a case study.


    10th Annual Protein and Engineering Summit (PEGS), at which Eleven Biotherapeutics researchers presented data demonstrating the power of Eleven’s AMP-Rx platform to design and engineer novel protein therapeutics. Eleven’s presentation topics included modulating cytokines to treat front and back of eye disease such as IL-1 inhibition with EBI-005, IL-6 inhibition with EBI-029 and IL-17 inhibition with EBI-028 and designing topical treatments of ocular surface inflammatory disorders, such as EBI-005, to have low immunogenicity potential.



    Completed our initial public offering, with aggregate net proceeds of approximately $50.2 million, net of underwriting discounts and commissions and other offering expenses payable by us.


    Strengthened our leadership team with the appointment of ophthalmic industry veterans, including Paul Chaney as a member of our Board of Directors and Gary Sternberg, M.D., M.B.A., as Executive Vice President Corporate and Business Development.


    Added to the Russell Indexes on March 31, 2014, including the Russell 2000 and Russell 3000 index.

Upcoming Events and Presentations:


    Contact Lens Association of Ophthalmologists (CLAO), June 14, 2014


    International Society of Ophthalmologists (ISOPT), June 19-22, 2014

Financial Results

Revenues were $0.6 million during the quarter ended March 31, 2014 compared to $0 for the quarter ended March 31, 2013 and include amounts from the Thrombogenics collaboration which began in May 2013.

Total operating expenses for the quarter ended March 31, 2014 were $7.8 million compared to $5.4 million for the quarter ended March 31, 2013.



Net cash used in operating activities during the quarter ended March 31, 2014 was $5.0 million compared to $5.4 million for the quarter ended March 31, 2013. Eleven Biotherapeutics held $54.0 million in cash and cash equivalents as of March 31, 2014. We have identified and are planning additional expenditures that we believe will enhance the likelihood of EBI-005’s clinical and commercial success. A majority of these additional expenses will be contingent upon positive results from our first Phase 3 clinical study. If we make such expenditures, the Company expects to have sufficient cash and cash equivalents to fund current operations into the first quarter of 2016. This is an update from previous guidance in which cash was forecast to be sufficient into the second half of 2016.

Net loss applicable to common stockholders was $7.7 million, or $0.80 per share, for the quarter ended March 31, 2014, compared to net loss applicable to common stockholders of $6.4 million, or $5.14 per share, for the quarter ended March 31, 2013.

Conference Call Information:

Eleven Biotherapeutics management team will host a conference call and audio webcast today at 8:30 a.m. ET to discuss the first quarter 2014 results and provide a corporate update. To access the conference call, please dial (844) 831-3025 (domestic) or (315) 625-6887 (international) at least five minutes prior to the start time and refer to conference ID 44137135.

An audio webcast of the call will also be available on the Investors & Media section of the Company’s website An archived webcast will be available on the Company’s website approximately two hours after the event and will be available for 30 days.

About EBI-005

Eleven Biotherapeutics’ most advanced product candidate is EBI-005, which was designed, engineered and generated using the Company’s AMP-Rx platform and is being developed as a topical treatment for dry eye disease and allergic conjunctivitis. In 2013, Eleven Biotherapeutics completed a Phase 1b/2a clinical trial of EBI-005 in patients with moderate to severe dry eye disease. The EBI-005 program is based on the role that elevated levels of the inflammatory cytokine interleukin-1, or IL-1, play in the initiation and maintenance of the inflammation and pain associated with dry eye disease and the redness and itching associated with allergic conjunctivitis. EBI-005 is currently being evaluated in a pivotal Phase 3 clinical study in subjects with dry eye disease and a Phase 2 clinical study in subjects with allergic conjunctivitis.

About Eleven Biotherapeutics

Eleven Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, the Company’s understanding of the structural biology of cytokines and the Company’s ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects.



Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, advancement or maturation of its product candidates and product pipeline, clinical development of the Company’s therapeutic candidates, including expectations regarding timing of initiation of clinical trials, patient enrollment and availability of results, regulatory requirements for initiation of clinical trials and registration of product candidates, sufficiency of cash resources and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from ongoing clinical trials, whether results of early clinical trials will be indicative of the results of future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals and other factors discussed in the “Risk Factors” section of the Company’s annual report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2014 and other reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.



Gregory Perry, Eleven Biotherapeutics


Gina Nugent, The Yates Network






(in thousands, except per share data)


     Three Months Ended
March 31,
     2014     2013  

Collaboration revenue

   $ 568      $ —    

Operating expenses:


Research and development

     5,819        4,496   

General and administrative

     1,938        939   







Total operating expenses

     7,757        5,435   







Loss from operations

     (7,189     (5,435







Other income (expense):


Other (expense) income, net

     51        2   

Interest expense

     (84     (79







Total other expense, net

     (33     (77







Net loss and comprehensive loss

   $ (7,222   $ (5,512







Cumulative preferred stock dividends

     (519     (893







Net loss applicable to common stockholders

   $ (7,741   $ (6,405







Net loss per share applicable to common stockholders—basic and diluted

   $ (0.80   $ (5.14







Weighted-average number of common shares used in net loss per share applicable to common stockholders—basic and diluted

     9,635        1,247   












(in thousands)


     March 31,     December 31,  
     2014     2013  



Current assets:


Cash and cash equivalents

   $ 53,964      $ 7,942   

Prepaid expenses and other current assets

     443        88   







Total current assets

     54,407        8,030   

Property and equipment, net

     708        759   

Restricted cash

     94        94   

Other assets

     18        2,354   







Total assets

   $ 55,227      $ 11,237   







Liabilities, convertible preferred stock, and stockholders’ equity (deficit)


Current liabilities:


Accounts payable

   $ 3,070      $ 1,746   

Accrued expenses

     457        850   

Notes payable, current portion

     1,642        1,642   

Deferred revenue, current portion

     1,134        1,115   







Total current liabilities

     6,303        5,353   

Deferred revenue, net of current portion

     223        355   

Restricted stock liability

     8        10   

Notes payable, net of current portion

     2,466        2,876   

Warrant liability

     —          297   

Series A convertible preferred stock

     —          45,035   

Series B convertible preferred stock

     —          11,643   

Stockholders’ equity (deficit):


Common stock

     16        2   

Additional paid-in capital

     111,027        3,260   

Accumulated deficit

     (64,816     (57,594







Total stockholders’ equity (deficit)

     46,227        (54,332







Total liabilities, convertible preferred stock and stockholders’ equity (deficit)

   $ 55,227      $ 11,237